PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Biolinerx Ltd.

USPTO PatentsView assignee record - 17 granted patents across 3 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).

Explore the portfolio See the ranking
17
Total patents granted
3
CPC technology areas
8.5
Avg claims per patent
-
5-year filing velocity

The verdict

Biolinerx holds 17 US patents across 3 technology areas, rank #16,647 of 50,000 tracked assignees.

#16,647
of 50,000 US assignees by volume
Top 34%
by Innovation Score (41.2/100)
8.5
avg claims per patent

Portfolio overview

BioLineRx Ltd. has been granted 17 US utility patents between 2020 and 2025, placing BioLineRx Ltd. at rank #16,647 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 8.5 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, BioLineRx Ltd. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 41.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 17 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. BioLineRx Ltd.'s 8.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark BioLineRx Ltd. against peers pursuing similar technology classes.

How does BioLineRx compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows BioLineRx holds 17 patents, placing it at rank #16,647 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

BioLineRx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

024681012 20202022202320242025 3
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
BioLineRx Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 2 11.8%
2022 1 5.9%
2023 10 58.8%
2024 1 5.9%
2025 3 17.6%

Which technologies does BioLineRx Ltd. patent most?

Top 3 of 3 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple

Where it ranks

Overall rank by patents

#16,647

Across all tracked assignees

Innovation Score

41.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does BioLineRx Ltd. hold?
BioLineRx Ltd. holds 17 US granted patents filed between 2020 and 2025, spanning 3 technology areas.
What is BioLineRx Ltd.'s Innovation Score?
BioLineRx Ltd. has an Innovation Score of 41.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does BioLineRx Ltd. focus on?
BioLineRx Ltd.'s top technology area is C07K (PEPTIDES) with 17 patents. The company has filed patents in 3 CPC subclasses total.
Is BioLineRx Ltd.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for BioLineRx Ltd..
What does claim depth mean for BioLineRx Ltd.'s patents?
BioLineRx Ltd.'s patents average 8.5 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the BioLineRx Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Biolinerx's 17 grants land it in the top 34% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Biolinerx ranks #16,647 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

C07K technology

BioLineRx Ltd.'s primary CPC class, all holders and yearly trends
Top 50 patent holders

See where BioLineRx Ltd. ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov